GlassScriptPhysician profile
Deidre Mills
NPI 1720464225
$4,700.14
in general payments reported to CMS, 2019-2025
36 companies · $1,028 in 2025
The $1,028 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $741 · 2022: $838 · 2023: $779 · 2024: $1,314 · 2025: $1,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,113 · Education: $8.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,112.53 |
| Education | $8.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $443.01 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Radius Health, INC. | $435.21 | 2021-2025 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $424.08 | 2021-2025 | |
| Novo Nordisk INC | $400.43 | 2021-2025 | Wegovy |
| Abbott Laboratories | $397.38 | 2021-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $388.90 | 2021-2025 | |
| Amgen INC. | $321.61 | 2021-2025 | Tepezza, Repatha, Evenity |
| Dexcom, INC. | $258.88 | 2021-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $255.07 | 2022-2024 | Recorlev, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.79 | 2021-2025 | Jardiance |
| Corcept Therapeutics | $159.66 | 2021-2025 | Korlym |
| Ascendis Pharma Endocrinology INC | $105.33 | 2022-2024 | |
| Tandem Diabetes Care, INC. | $86.21 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Esperion Therapeutics, INC. | $69.24 | 2021-2022 | |
| Kyowa Kirin, INC. | $65.40 | 2024-2025 | Crysvita |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $52.92 | 2023-2024 | Omnipod |
| Rhythm Pharmaceuticals, INC. | $49.43 | 2025 | Imcivree |
| Intuity Medical INC | $47.71 | 2022 | |
| Azurity Pharmaceuticals, INC. | $46.90 | 2023-2025 | Triptodur, Triptodur |
| Cequr Corporation | $46.62 | 2024-2025 | Cequr Simplicity |
| Recordati_rare_diseases_inc. | $44.69 | 2023 | Isturisa, Signifor Lar |
| Amarin Pharma, INC. | $39.20 | 2021 | |
| Alexion Pharmaceuticals, INC. | $32.37 | 2022-2023 | Strensiq |
| Madrigal Pharmaceuticals | $26.59 | 2025 | Rezdiffra |
| Halozyme INC | $25.39 | 2023 | |
| Chiesi USA, INC. | $25.00 | 2025 | Mycapssa |
| Amneal Pharmaceuticals LLC | $24.99 | 2024 | Unithroid |
| Tolmar, INC. | $24.13 | 2024 | |
| Novartis Pharmaceuticals Corporation | $22.97 | 2024 | |
| Pfizer INC. | $20.43 | 2022 | |
| Sequel Med Tech, LLC | $19.43 | 2025 | Twiist |
| Ionis Pharmaceuticals, INC. | $19.41 | 2025 | Tryngolza |
| Ibsa Pharma INC. | $19.02 | 2024 | Tirosint, Licart |
| Medtronic, INC. | $16.78 | 2021 | |
| Abbvie INC. | $15.67 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $15.29 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deidre Mills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.